Inhibin beta B: A useful tumor marker in uterine endometrioid adenocarcinomas?

Histology and Histopathology

Volumn 26, Issue 11, 2011, Pages 1415-1422

  Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Endometrial cancer; Endometrioid adenocarcinoma; Immunohistochemistry; Inhibin betab; Prognosis; Survival

Indexed keywords

INHBB PROTEIN, HUMAN; INHIBIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER GRADING; CANCER STAGING; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBIN-BETA SUBUNITS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053199530     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Adkins H.B., Bianco C., Schiffer S.G., Rayhorn P., Zafari M., Cheung A.E., Orozco O., Olson D., De Luca A., Chen L.L., Miatkowski K., Benjamin C., Normanno N., Williams K.P., Jarpe M., LePage D., Salomon D. and Sanicola M. (2003). Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J. Clin. Invest. 112, 575-587.
2. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E. and Vergote I. (2005). Endometrial cancer. Lancet 366, 491-505.
3. Baselga J., Rothenberg M.L., Tabernero J., Seoane J., Daly T., Cleverly A., Berry B., Rhoades S.K., Ray C.A., Fill J., Farrington D.L., Wallace L.A., Yingling J.M., Lahn M., Arteaga C. and Carducci M. (2008). TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers 13, 217-236.
4. Bassarak N., Blankenstein T., Bruning A., Dian D., Bergauer, F., Friese, K. and Mylonas I. (2010). Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer 10, 224.
5. Brown C.W., Houston-Hawkins D.E., Woodruff T.K. and Matzuk M.M. (2000). Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions. Nat. Genet. 25, 453-457.
6. Brüning A., Jückstock J.K., Blankenstein T., Makovitzky J., Kunze S. and Mylonas I. (2010). The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol. Histopathol. 25, 1447-1456.
7. Buijs J.T., Henriquez N.V., van Overveld P.G., van der Hors, G., ten Dijke P. and van der Pluijm G. (2007). TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin. Exp. Metastasis 24, 609-617.
8. Burdette J.E. and Woodruff T.K. (2007). Activin and estrogen crosstalk regulates transcription in human breast cancer cells. Endocr. Relat. Cancer 14, 679-689.
9. Caniggia I., Lye S.J. and Cross J.C. (1997). Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology 138, 3976-3986.
10. Chen F., Jiang X., Chen X., Liu G. and Ding J. (2007). Effects of downregulation of inhibin alpha gene expression on apoptosis and proliferation of goose granulosa cells. J. Genet. Genomics 34, 1106-1113
11. Chen Y.G., Lui H.M., Lin S.L., Lee J.M. and Ying S.Y. (2002). Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp. Biol. Med. (Maywood) 227, 75-87.
12. de Kretser D.M., Hedger M.P., Loveland K.L. and Phillips D.J. (2002). Inhibins, activins and follistatin in reproduction. Hum. Reprod. Update 8, 529-541.
13. Denkova R., Bourneva V., Staneva-Dobrovski L., Zvetkova E., Baleva K., Yaneva E., Nikolov B., Ivanov I., Simeonov K., Timeva T. and Yankov M. (2004). In vitro effects of inhibin on apoptosis and apoptosis related proteins in human ovarian granulosa cells. Endocr. Regul. 38, 51-55.
14. Djouad F., Jackson W.M., Bobick B.E., Janjanin S., Song Y., Huang G.T. and Tuan R.S. (2010). Activin A expression regulates multipotency of mesenchymal progenitor cells. Stem Cell Res. Ther. 1, 11.
15. Farnworth P.G., Stanton P.G., Wang Y., Escalona R., Findlay J.K. and Ooi G.T. (2006). Inhibins differentially antagonize activin and bone morphogenetic protein action in a mouse adrenocortical cell line. Endocrinology 147, 3462-3471.
16. FIGO stages (announcements). (1989). Gynecol. Oncol. 35, 125-127.
17. Florio P., Gabbanini M., Borges L.E., Bonaccorsi L., Pinzauti S., Reis F.M., Boy Torres P., Rago G., Litta P. and Petraglia F. (2010). Activins and related proteins in the establishment of pregnancy. Reprod. Sci. 17, 320-330.
18. Gingelmaier A., Bruning A., Kimmich T., Makovitzky J., Bergauer F., Schiessl B., Friese K. and Mylonas I. (2010). Inhibin/activin-betaE subunit is expressed in normal and pathological human placental tissue including chorionic carcinoma cell lines. Arch. Gynecol. Obstet. 283, 223-230.
19. Gregory S.J. and Kaiser U.B. (2004). Regulation of gonadotropins by inhibin and activin. Semin. Reprod. Med. 22, 253-267.
20. He Z.Y., Liu H.C., Mele C.A., Barmat L., Veeck L.L., Davis O. and Rosenwaks Z. (1999). Expression of inhibin/activin subunits and their receptors and binding proteins in human preimplantation embryos. J. Assist. Reprod. Genet. 16, 73-80.
21. Jereczek-Fossa B., Badzio A. and Jassem J. (1999). Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int. J. Gynecol. Cancer 9, 285-294.
22. Jeruss J.S., Sturgis C.D., Rademaker A.W. and Woodruff T.K. (2003). Down-regulation of activin, activin receptors, and Smads in highgrade breast cancer. Cancer Res. 63, 3783-3790.
23. Jones R.L., Findlay J.K., Farnworth P.G., Robertson, D.M., Wallace E. and Salamonsen L.A. (2006). Activin A and inhibin A differentially regulate human uterine matrix metalloproteinases: potential interactions during decidualization and trophoblast invasion. Endocrinology 147, 724-732.
24. Jones R.L., Salamonsen L.A. and Findlay J.K. (2002). Activin A promotes human endometrial stromal cell decidualization in vitro. J. Clin. Endocrinol. Metab. 87, 4001-4004.
25. Kaplan E.L. and Meier P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
26. Katik I., Mackenzie-Kludas C., Nicholls C., Jiang F.X., Zhou S., Li H. and Liu J.P. (2009). Activin inhibits telomerase activity in cancer. Biochem. Biophys. Res. Commun. 389, 668-672.
27. Käufl S.D., Kuhn C., Kunze S., Shabani N., Bruning, A., Friese K. and Mylonas I. (2010). Inhibin/activin-betaC subunit does not represent a prognostic parameter in human endometrial cancer. Arch. Gynecol. Obstet. 284, 199-207.
28. Kimmich T., Bruning A., Kauf S.D., Makovitzky J., Kuhn C., Jeschke U., Friese K. and Mylonas I. (2010). Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch. Gynecol. Obstet. 282, 185-191.
29. Makanji Y., Temple-Smith P.D., Walton K.L., Harrison, C.A. and Robertson D.M. (2009). Inhibin B is a more potent suppressor of rat follicle-stimulating hormone release than inhibin a in vitro and in vivo. Endocrinology 150, 4784-4793.
30. Matzuk M.M., Finegold M.J., Mathe J.P., Krummen L., Lu H. and Bradley A. (1994). Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc. Natl. Acad. Sci. USA. 91, 8817-8821.
31. Matzuk M.M., Finegold M.J., Su J.G., Hsueh A.J. and Bradley A. (1992). Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360, 313-319.
32. McCarthy S.A. and Bicknell R. (1993). Inhibition of vascular endothelial cell growth by activin-A. J. Biol. Chem. 268, 23066-23071.
33. Mylonas I. (2010a). Inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid carcinomas: Prognostic significance and clinical implications. Eur. J. Cancer 46, 2485-2493.
34. Mylonas I. (2010b). Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol. Rep. 24, 385-393.
35. Mylonas I. (2011a). Inhibin-ßA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation?. Arch. Gynecol. Obstet. 284, 467-476.
36. Mylonas I. (2011b). Inhibin-a subunit expression in uterine endometrioid adenocarcinomas and endometrial cancer cell lines: a potential prognostic factor. Int. J. Mol. Med. 27, 309-318.
37. Mylonas I., Jeschke U., Wiest I., Hoeing A., Vogl J., Shabani N., Kuhn C., Schulze S., Kupka M.S. and Friese K. (2004). Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem. Cell Biol. 122, 461-471.
38. Mylonas I., Worbs S., Shabani N., Kuhn C., Kunze S., Schulze S., Dian D., Gingelmaier A., Schindlbeck C., Bruning A., Sommer H., Jeschke U. and Friese K. (2009). Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: Analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur. J. Cancer 45, 1304-1314.
39. Mylonas I., Bruning A., Shabani N., Kunze S. and Kupka M.S. (2010). Evidence of inhibin/activin subunit betaC and betaE synthesis in normal human endometrial tissue. Reprod. Biol. Endocrinol. 19, 143.
40. Mylonas I., Matsingou C., Käufl S.D. and Bruning A. (2011). Inhibin/activin betaE-subunit in uterine endometrioid adenocarcinoma and endometrial cancer cell lines: from immunohistochemistry to clinical testing?. Gynecol. Oncol. 122, 132-140.
41. Ni X., Luo S., Minegishi T. and Peng, C. (2000). Activin A in JEG-3 cells: potential role as an autocrine regulator of steroidogenesis in humans. Biol. Reprod. 62, 1224-1230.
42. Pecorelli S. (2009). Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 105, 103-104.
43. Petraglia F., Florio P., Luisi S., Gallo R., Gadducci A., Vigano P., Di Blasio A.M., Genazzani A.R. and Vale W. (1998a). Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J. Clin. Endocrinol. Metab. 83, 1194-1200.
44. Petraglia F., Luisi S., Pautier P., Sabourin J.C., Rey R., Lhomme C. and Bidart J.M. (1998b). Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. J. Clin. Endocrinol. Metab. 83, 1029-1032.
45. Phillips D.J., de Kretser D.M. and Hedger M.P. (2009). Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 20, 153-164.
46. Prat J. (2004). Prognostic parameters of endometrial carcinoma. Hum Pathol 35, 649-662.
47. Ramachandran A., Marshall E.S., Love D.R., Baguley B.C. and Shelling A.N. (2009). Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett. 285, 157-165.
48. Ramos-Mejia V., Melen G.J., Sanchez L., Gutierrez-Aranda I., Ligero G., Cortes J.L., Real P.J., Bueno C. and Menendez P. (2010). Nodal/Activin signaling predicts human pluripotent stem cell lines prone to differentiate toward the hematopoietic lineage. Mol. Ther.
49. Razanajaona D., Joguet S., Ay A.S., Treilleux I., Goddard-Leon S., Bartholin L. and Rimokh R. (2007). Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res. 67, 7223-7229.
50. Risbridger G.P., Ball E.M., Wang H., Mellor S.L. and Peehl D.M. (2004). Re-evaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer. Mol. Cell Endocrinol. 225, 73-76.
51. Risbridger G.P., Schmitt J.F. and Robertson D.M. (2001). Activins and inhibins in endocrine and other tumors. Endocr. Rev. 22, 836-858.
52. Salogni L., Musso T., Bosisio D., Mirolo M., Jala V.R., Haribabu B., Locati M. and Sozzani S. (2009). Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood 113, 5848-5856.
53. Seder C.W., Hartojo W., Lin L., Silvers A.L., Wang Z., Thomas D.G., Giordano T.J., Chen G., Chang A.C., Orringer M.B. and Beer D.G. (2009). Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia 11, 388-396.
54. Shabani N., Kuhn C., Kunze S., Schulze S., Mayr D., Dian D., Gingelmaier, A., Schindlbeck, C., Willgeroth, F., Sommer, H., Jeschke, U., Friese, K. and Mylonas, I. (2007). Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur. J. Cancer 43, 2434-2444.
55. Shav-Tal Y. and Zipori D. (2002). The role of activin a in regulation of hemopoiesis. Stem Cells 20, 493-500.
56. Smith J.C., Price B.M., Van Nimmen K. and Huylebroeck D. (1990). Identification of a potent Xenopus mesoderm-inducing factor as a homologue of activin A. Nature 345, 729-731.
57. Stoikos C.J., Salamonsen L.A., Hannan N.J., O'Connor A.E., Rombauts L. and Dimitriadis E. (2010). Activin A regulates trophoblast cell adhesive properties: implications for implantation failure in women with endometriosis-associated infertility. Hum. Reprod. 25, 1767-1774.
58. Thompson T.B., Cook R.W., Chapman S.C., Jardetzky T.S. and Woodruff T.K. (2004). Beta A versus beta B: is it merely a matter of expression? Mol Cell Endocrinol 225, 9-17.
59. Tsai Z.Y., Singh S., Yu S.L., Kao L.P., Chen B.Z., Ho B.C., Yang P.C. and Li S.S. (2010). Identification of microRNAs regulated by activin A in human embryonic stem cells. J. Cell. Biochem. 109, 93-102.
60. Tsuchida K., Nakatani M., Hitachi K., Uezumi A., Sunada Y., Ageta H. and Inokuchi K. (2009). Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal. 7, 15.
61. Vale W., Rivier C., Hsueh A., Campen C., Meunier H., Bicsak T., Vaughan J., Corrigan A., Bardin W., Sawchenko P., Petraglia F., Yu J., Plotsky P., Spiess J. and Rivier J. (1988). Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog. Horm. Res. 44, 1-34.
62. Vale W., Wiater E., Gray P., Harrison C., Bilezikjian L. and Choe S. (2004). Activins and inhibins and their signaling. Ann. N Y Acad. Sci. 1038, 142-147.
63. Vihko K.K., Blauer M., Puistola U. and Tuohimaa P. (2003). Activin B in patients with granulosa cell tumors: serum levels in comparison to inhibin. Acta Obstet. Gynecol. Scand. 82, 570-574.
64. Watabe T. and Miyazono K. (2009). Roles of TGF-beta family signaling in stem cell renewal and differentiation. Cell Res. 19, 103-115.
65. Weissenbacher T., Bruning A., Kimmich T., Makovitzky J., Gingelmaier A. and Mylonas I. (2010). Immunohistochemical labeling of the inhibin/activin betaC subunit in normal human placental tissue and chorionic carcinoma cell lines. J. Histochem. Cytochem. 58, 751-757.
66. Welt C., Sidis Y., Keutmann H. and Schneyer A. (2002). Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp. Biol. Med. (Maywood) 227, 724-752.
67. Worbs S., Shabani N., Mayr D., Gingelmaier A., Makrigiannakis A., Kuhn C., Jeschke U., Kupka, M. S., Friese K. and Mylonas I. (2007). Expression of the inhibin/activin subunits (-alpha, -betaA and -betaB) in normal and carcinogenic endometrial tissue: Possible immunohistochemical differentiation markers. Oncol. Rep. 17, 97-104.
68. Xia Y. and Schneyer A.L. (2009). The biology of activin: recent advances in structure, regulation and function. J. Endocrinol. 202, 1-12.
69. Xuan Y.H., Choi, Y.L., Shin Y.K., Ahn G.H., Kim K.H., Kim W.J., Lee H.C. and Kim S.H. (2007). Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease. Histol. Histopathol. 22, 227-234.